Neuronasal, Inc. is a clinical-stage pharmaceutical company founded in 2015 in response to the clear and growing unmet needs of mTBI patients. Neuronasal leverages existing science, combined with a cutting-edge delivery mechanism, to develop a potentially ground-breaking treatment for mTBI. This innovation will fill the gap for these patients, as there is currently no approved treatment available. In partnership with ATAI, Neuronasal is using formulations, devices and biomarkers to efficiently develop these new treatments. Neuronasal, Inc. is headquartered in Pennsylvania.
View Top Employees from Neuronasal| Website | http://www.neuronasal.com |
| Revenue | $5 million |
| Employees | View employees |
| Address | 2465 Citation St, Wexford, Pennsylvania 15090, US |
| Phone | (617) 714-3075 |
| Industry | Hospitals & Clinics, Healthcare |
| SIC | SIC Code 80 Companies, SIC Code 809 Companies |
| NAICS | NAICS Code 621498 Companies, NAICS Code 6214 Companies, NAICS Code 621 Companies, NAICS Code 62 Companies, NAICS Code 62149 Companies |
Looking for a particular Neuronasal employee's phone or email?
Neuronasal Questions
The Neuronasal annual revenue was $5 million in 2024.
Neuronasal is based in Wexford, Pennsylvania.
The NAICS codes for Neuronasal are [621498, 6214, 621, 62, 62149].
The SIC codes for Neuronasal are [80, 809].
